kinnate biopharma inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. the company's lead product candidate is kin002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. its other products in preclinical stage include kin003, which are small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (fgfr)2 and fgfr3 genes; and small molecule research programs, including a cyclin-dependent kinase 12 inhibitor in its kin004 program. kinnate biopharma inc. was founded in 2018 and is headquartered in san diego, california.